



# VENMAX

DRUGS AND PHARMACEUTICALS LIMITED.

Venmax Drugs and Pharmaceuticals Ltd.  
H.No. 1-140, Rajeswari Ware House,  
Opposite to Sri Convention, Kompally,  
Quthbullapur, Hyderabad,  
Medchal Dist-500014, Telangana.  
E-mail: venmaxdrugs@gmail.com

30<sup>th</sup> July, 2022

To,  
The Secretary  
BSE Limited  
Phiroze Jeejeebhoy Towers, Dalal Street  
MUMBAI - 400 001

**Scrip code: 531015**

Dear Sir/Madam,

**Sub:** Outcome of Board Meeting held on 30<sup>th</sup> July, 2022  
**Ref:** Pursuant to Reg.30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015,

With reference to the subject cited above, we wish to inform you that the Board of Directors of the Company at its meeting held on Saturday, the 30<sup>th</sup> July, 2022 at 4.00 P.M at registered office of the Company, inter alia,

- (i) Approved the Un Audited Standalone Financial Results of the Company for the quarter ended 30<sup>th</sup> June, 2022 & Auditors Limited Review Report thereon;
- (ii) Approved the Shifting of Registered office of the Company to Shed No.22, Plot No.84, Phase-1, IDA Cherlapally, Hyderabad – 500051, Telangana within local limits of city.

The meeting commenced at 4.00 p.m. and concluded at 4.30 p.m.

Request you to take the above information on records.

Thanking you,

Yours Faithfully,

For Venmax Drugs and Pharmaceuticals Limited

  
N. Krishnaiah  
Director  
DIN: 07279009





**Independent Auditor's Report on Quarterly Unaudited financial Results of M/s VENMAX DRUGS AND PHARMACEUTICALS LIMITED pursuant to Regulation 33 of the SEBI(Listing and Obligations and Disclosure requirements) Regulations, 2015.**

To the Board of Directors of **VENMAX DRUGS AND PHARMACEUTICALS LIMITED**

We have reviewed the accompanying statement of unaudited financial results of **VENMAX DRUGS AND PHARMACEUTICALS LIMITED** ('The Company') for the quarter ended June 30, 2022. This statement is the responsibility of the company's management and has been approved by the board of directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standards on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the entity' issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free from material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian accounting standards specified under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting principles and policies has not disclosed the information required to be disclosed in terms of the regulation 33 of the SEBI (Listing Obligations and disclosure requirements) regulations, 2015 including the manner in which it is to be disclosed or that it contains any material misstatements..

For **NSVR & Associates LLP**  
Chartered Accountants  
FRN: 008801S/S200067

  
  
Suresh Gannamani  
Partner  
Membership No.226870  
UDIN: 22226870ANXWXO7271


Place: Hyderabad  
Date: 30/07/2022



# VENMAX

DRUGS AND PHARMACEUTICALS LIMITED.

Venmax Drugs and Pharmaceuticals Ltd.  
H.No. 1-140, Rajeswari Ware House,  
Opposite to Sri Convention, Kompally,  
Quthbullapur, Hyderabad,  
Medchal Dist-500014, Telangana.  
E-mail: venmaxdrugs@gmail.com

VENMAX DRUGS AND PHARMACEUTICALS LIMITED				
H.No.1-140, Rajeswari Ware House, Opposite to Sri Convention, Kompally, Quthbullapur Hyderabad Rangareddi TG 500055 (CIN: L24230TG1988PLC009102)				
(in Rs Lakhs)				
Statement Of Un-Audited Results For The Quarter Ended 30 June 2022				
Particulars	Quarter ended June 30, 2022	Quarter ended March 31, 2022	Quarter ended June 30, 2021	Year ended March 31, 2021
	(Un Audited)	(Audited)	(Audited)	(Audited)
<b>Income</b>				
Revenue from operations	0.00	0.00	0.00	16.79
<b>Total Revenue from operations</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>16.79</b>
Other income	5.00	198.30	0.00	18.14
<b>Total Income</b>	<b>5.00</b>	<b>198.30</b>	<b>0.00</b>	<b>34.93</b>
<b>Expenses</b>				
Purchases	0.00	0.00	0.00	7.86
Changes in Inventory	0.00	0.00	0.00	21.58
Employee benefits expense	0.30	0.30	0.30	6.27
Finance costs	0.00	0.00	0.00	0.09
Depreciation and amortization expense	0.20	0.23	0.23	1.29
Other expenses	1.37	2.88	2.88	19.27
<b>Total Expenses</b>	<b>1.87</b>	<b>3.41</b>	<b>3.41</b>	<b>56.35</b>
<b>Profit before tax</b>	<b>3.13</b>	<b>194.89</b>	<b>-3.41</b>	<b>-21.42</b>
<b>Tax expense</b>				
(1) Current tax	0.00	0.00	0.00	0.00
(2) Deferred tax	0.16	-0.05	0.01	0.63
<b>Net Profit for the Period</b>	<b>2.97</b>	<b>194.94</b>	<b>-3.42</b>	<b>-22.05</b>
<b>Other comprehensive income (OCI)</b>				
(a) (i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
(ii) Tax on items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
(b) (i) Items that will be reclassified to profit or loss				
(ii) Exchange rate fluctuations on monetary items reclassified to profit or loss				
<b>Total Other Comprehensive income</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>Total Comprehensive income</b>	<b>2.97</b>	<b>194.94</b>	<b>-3.42</b>	<b>-22.05</b>
<b>Paid-up Equity Share Capital</b> (Rs.,10/- per Equity Share)	523.89	523.89	523.89	523.89
<b>Other Equity</b>	0.00	0.00	0.00	-786.28
<b>Earnings per equity share</b> (Face value of Rs.10/- each)				
(1) Basic	0.06	3.72	-0.07	-0.42
(2) Diluted	0.06	3.72	-0.07	-0.42
<b>Notes</b>				
a) The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) (Amendment) rules 2016.				
b) The above financial results recommended by the Board Committee are considered and approved by the Board of Directors in their meeting held on 30th July, 2022				
c) The above statement have been prepared to the extent applicable, in accordance with the companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under Section 133 of the Companies Act, 2013 and other recognised Accounting Practices and Policies adopted by the Company w.e.f.01.04.2017. The financial results of the previous periods duly complied with Ind AS have not been subjected to review or audit, however, the Management has exercised necessary diligence to ensure that the financial results provide a true and fair view of the Company's affairs.				
d) The Statutory Auditors of the Company have carried out "Limited Review" of the above unaudited financial results and their Report has been placed before the Board at the said Meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015.				
e) Estimation uncertainty relating to the global health pandemic on COVID-19 The management has considered the possible effects, if any, that may result from the pandemic relating to COVID - 19 on the carrying amounts of trade receivables & inventories. In assessing the recoverability of receivables, the Company has considered internal and external information upto the date of approval of these financial results including credit reports and economic forecasts. The Company has performed sensitivity analysis on the assumptions used and based on current indicators of future economic conditions, the Company expects to recover the carrying amount of these assets. The impact of the global health pandemic may be different from that estimated as at the date of approval of these financial results and the Company				
f) The Company is engaged in activities of trading of bulk drugs, intermediates and biotech products. Hence Segment reporting is not applicable.				
				For and on Behalf of Board of Directors
				 <b>N. Krishniah</b> ( Director ) DIN: 07279009
Date : 30/07/2022. Place : Hyderabad.				